Callahan started her lengthy career as an intern at Young & Rubicam ... He served as president from 2006 to 2018 and secured clients like AstraZeneca, Sanofi and AbbVie. After he stepped down as ...

The firm built internship and development programs to ... as did healthcare (pharmaceutical Eli Lilly LLY and biotech AbbVie ABBV) and materials (cement-maker CRH CRH and metals company Reliance ...

JAMA Intern Med. 2022;182(4):418-425 ... Bioequivalence studies for generic drug development. AbbVie. Synthroid (levothyroxine sodium) tablets, for oral use. Neolpharma. Levo-T (levothyroxine sodium) ...

To battle those disruptions, AbbVie, maker of three migraine treatment options, launched a contest this year to provide support for people whose migraines create obstacles in reaching their ...

A splashy recent acquisition by the company might not be panning out. Just before the market open on Monday, AbbVie revealed that its emraclidine schizophrenia treatment did not meet its primary ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...

An AbbVie schizophrenia drug acquired as part of a multi-billion dollar deal has failed two mid-stage studies, dealing a setback to the company’s plans to compete with a Bristol Myers Squibb ...

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine ...

AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got the drug through its recent $9 billion ...